See more : Unichem Laboratories Limited (UNICHEMLAB.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Intensity Therapeutics, Inc. (INTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intensity Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- IperionX Limited (IPX.AX) Income Statement Analysis – Financial Results
- VSTECS Holdings Limited (0856.HK) Income Statement Analysis – Financial Results
- PT Mahaka Radio Integra Tbk (MARI.JK) Income Statement Analysis – Financial Results
- SINOPEC Engineering (Group) Co., Ltd. (2386.HK) Income Statement Analysis – Financial Results
- Marvel Gold Limited (GRXMF) Income Statement Analysis – Financial Results
Intensity Therapeutics, Inc. (INTS)
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 147.00K | 179.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -147.00K | -179.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.79M | 5.13M | 5.86M | 5.05M | 4.44M |
| General & Administrative | 3.53M | 2.42M | 2.16M | 1.17M | 1.24M |
| Selling & Marketing | -147.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.39M | 2.42M | 2.16M | 1.17M | 1.24M |
| Other Expenses | 0.00 | 47.65K | 115.51K | 118.76K | 144.99K |
| Operating Expenses | 8.17M | 7.55M | 8.01M | 6.22M | 5.68M |
| Cost & Expenses | 8.32M | 7.55M | 8.01M | 6.22M | 5.68M |
| Interest Income | 324.00K | 2.48K | 2.61K | 74.01K | 150.71K |
| Interest Expense | 305.00K | 81.78K | 16.77K | 0.00 | 0.00 |
| Depreciation & Amortization | 147.00K | 179.04K | 236.56K | 206.30K | 171.86K |
| EBITDA | -10.09M | -7.40M | -7.88M | -6.03M | -5.38M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.32M | -7.63M | -8.01M | -6.22M | -5.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.22M | 49.06K | 118.12K | 192.77K | 295.70K |
| Income Before Tax | -10.54M | -7.58M | -7.90M | -6.03M | -5.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -131.91K | -2.61K | -74.01K | -150.71K |
| Net Income | -10.54M | -7.45M | -7.89M | -5.96M | -5.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.38 | -0.57 | -0.60 | -0.45 | -0.40 |
| EPS Diluted | -1.38 | -0.57 | -0.60 | -0.45 | -0.40 |
| Weighted Avg Shares Out | 8.62M | 13.10M | 13.10M | 13.10M | 13.10M |
| Weighted Avg Shares Out (Dil) | 8.62M | 13.10M | 13.10M | 13.10M | 13.10M |
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
SHELTON, Conn. , Nov. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and...
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone INVINCIBLE-3 Study is recruiting and expected to...
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn. , Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery...
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
SHELTON, Conn. , Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors...
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Testing the efficacy and safety of Intensity's lead drug candidate, INT230-6, when combined with Standard-of-Care versus Standard-of-Care alone The endpoint is the change in pathological complete response rates SHELTON, Conn. and BERN, Switzerland , Oct. 31, 2024 /PRNewswire/ -- Intensity...
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SHELTON, Conn., Sept. 4, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that...
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in Europe Cash...
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Testing the efficacy and safety of our lead product candidate, INT230-6, as Monotherapy Compared with Systemic U.S. Standard-of-Care Chemotherapy SHELTON, Conn. , July 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused...
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
SHELTON, Conn. , May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune...
Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug
Mid-2024, Intensity Therapeutics will start Phase 3 and Phase 2/3 trials respectively in soft tissue sarcoma and triple-negative breast cancer. INT230-6 has shown up to 95% tumor necrosis, prolonged survival rates, immune activation, and abscopal effects in various cancers. INT230-6's...
Source: https://incomestatements.info
Category: Stock Reports